Disclosed is the use of a compound of Formula (I), or a salt, prodrug, hydrate, solvate or polymorph thereof in the preparation of a medicament for treatment or prevention of a disorder in a subject selected from blood cancers (such as leukaemia) and hematologic malignancies wherein: A is -C(R1)2-, -O- or -NR1- E is -NR1 G is -S-, -NR1- or -CR1R2- R1 and R2 are each independently selected from hydrogen, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, -(Z)n-aryl, -OR3, -C(O)R3, -C(O)OR3, -(Z)n-C(O)OR3 and -S(O)t- Z is independently selected from -C(R3)(R4)-, -C(O)-, -O-, -C(=NR3)-, -S(O)t- and -N(R3)- n is zero, one or two t is zero, one or two R3 and R4 are each independently selected from hydrogen, alkyl, aryl and heterocyclic and X and Y are each independently selected from O, S, N(R3) and C(R1)(R2). Of particular importance is the use of a compound of formula (I) which is 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (also known as TDZD-8).
